NCT06607185 2026-04-22
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
Clinical Trials
23 trialsNCT04580771 2026-04-15
A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02466971 2026-04-13
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04491942 2026-04-13
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03772028 2026-04-08
OVHIPEC-2
The Netherlands Cancer Institute
Phase 3 Active not recruiting
NCT04938583 2026-04-06
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
CanariaBio Inc.
Phase 1/2 Active not recruiting
NCT04430699 2026-03-19
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT01970722 2026-03-05
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03734692 2026-02-12
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
University of Pittsburgh
Phase 1/2 Active not recruiting
NCT04982237 2025-11-19
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Akeso
Phase 3 Active not recruiting
NCT02595879 2025-11-13
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06715592 2025-08-08
ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Active not recruiting
NCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT05406674 2025-07-20
CisCon
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT04634877 2025-06-09
KEYNOTE-B21
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06237257 2024-12-24
A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd
Phase 2 Active not recruiting
NCT01566240 2024-12-05
INTERLACE
University College, London
Phase 3 Active not recruiting
NCT05173987 2024-11-21
KEYNOTE-C93
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT02124421 2024-11-19
CRS/HIPEC
Mercy Medical Center
Phase 2 Active not recruiting
NCT04723875 2024-11-01
Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline
Huazhong University of Science and Technology
Phase 3 Active not recruiting
NCT05235516 2024-08-13
AK104-305
Akeso
Phase 3 Active not recruiting
NCT04000906 2024-05-24
Nab-PIPAC
University Hospital, Geneva
Phase 1 Active not recruiting
NCT06419673 2024-05-17
Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting